Clearside Biomedical to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Core Insights - Clearside Biomedical, Inc. is set to present a corporate update at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference on August 15, 2024, at 7:00 a.m. ET, with participation from Chief Medical Officer Victor Chong in a panel discussion on AMD [1] Company Overview - Clearside Biomedical, Inc. is a biopharmaceutical company focused on innovative delivery of therapies to the back of the eye through the suprachoroidal space (SCS®) [3] - The company utilizes its patented SCS Microinjector® for a non-surgical, repeatable procedure aimed at delivering various therapies to the macula, retina, or choroid, potentially preserving and improving vision in patients with serious eye diseases [3] - Clearside is developing a pipeline of small molecule product candidates for administration via its SCS Microinjector, with its lead program, CLS-AX (axitinib injectable suspension), currently in Phase 2b clinical testing for neovascular age-related macular degeneration (wet AMD) [3] - The company has also developed its first product, XIPERE® (triamcinolone acetonide injectable suspension), which is approved for suprachoroidal use and available in the U.S. through a commercial partner [3] - Clearside strategically partners its SCS injection platform with other companies to leverage additional ophthalmic therapeutic innovations [3]